ForSight VISION5, a clinical development stage firm, named John F. Maroney as its new president and Chief Executive Officer. The company, which focuses on ophthalmic diseases, also recently closed its Series B-1 financing, raising $9.3 million worth of investments. The fundraising was fronted by Technology Partners and supported by Delphi Ventures.
Maroney's previous position was at Delphi Ventures. He served a company's Managing Member. Delphi, a venture capital firm with focused on the healthcare sector, has over $1 billion in capital acquired across eight funds. Before that, Maroney was also President, Chief Executive Officer and Chairman of Endo Tex Interventional Systems, Inc. Endo Tex is a development stage start-up company focused on carotid artery stem commercialization.
Reacting on his newest position, Maroney said, ""I am thrilled to join and lead the exciting team at ForSight VISION5 brought together by Angela Macfarlane around the technology pioneered by Dr. Eugene de Juan, Jr. MD. The investors are truly a world class group and I feel privileged to work with each of them."
Join the Conversation